

CITATION REPORT

List of articles citing

**Ezetimibe: a review of its metabolism,
pharmacokinetics and drug interactions**

DOI: 10.2165/00003088-200544050-00002
Clinical Pharmacokinetics, 2005, 44, 467-94.

Source: <https://exaly.com/paper-pdf/39421285/citation-report.pdf>

Version: 2024-04-09

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
325	Current awareness: Pharmacoepidemiology and drug safety. 2005 , 14, i-xii		
324	Lipids for psychiatrists - an overview. 2005 , 19, 66-75		14
323	Treatment of dyslipidemia with lovastatin and ezetimibe in an adolescent with cholesterol ester storage disease. 2005 , 4, 26		48
322	Combination therapy with ezetimibe and simvastatin to achieve aggressive LDL reduction. 2006 , 4, 461-76		37
321	Drug Interactions of Medications Commonly Used in Diabetes. 2006 , 19, 202-211		36
320	Reaching goal in hypercholesterolaemia: dual inhibition of cholesterol synthesis and absorption with simvastatin plus ezetimibe. 2006 , 22, 511-28		49
319	Severe hepatic side effects of ezetimibe. 2006 , 4, 908-11		40
318	Lipoprotein effects of combined ezetimibe and colessevelam hydrochloride versus ezetimibe alone in hypercholesterolemic subjects: a pilot study. 2006 , 55, 1697-703		26
317	Methods to evaluate biliary excretion of drugs in humans: an updated review. 2006 , 3, 198-211		116
316	Evaluation of the potential for pharmacokinetic interaction between fenofibrate and ezetimibe: A phase I, open-label, multiple-dose, three-period crossover study in healthy subjects. 2006 , 28, 373-87		17
315	[Treatment of dyslipidemia: how and when to combine lipid lowering drugs]. 2006 , 50, 344-59		8
314	Ezetimibe for primary hypercholesterolemia. 2006 ,		
313	Interaction of single-dose ezetimibe and steady-state cyclosporine in renal transplant patients. 2006 , 46, 328-36		29
312	Ezetimibe: one step beyond in the battle against atherosclerosis. 2006 , 1, 255-266		1
311	Effects of ezetimibe on cyclosporine pharmacokinetics in healthy subjects. 2006 , 46, 321-7		18
310	Ezetimibe in renal transplant patients with hyperlipidemia resistant to HMG-CoA reductase inhibitors. 2006 , 81, 804-7		29
309	Management of lipid abnormalities associated with end-stage renal disease. 2006 , 19, 391-401		1

308	Effect of ezetimibe on insulin sensitivity and lipid profile in obese and dyslipidaemic patients. 2006 , 20, 143-6	22
307	Ezetimibe for the treatment of uncontrolled hypercholesterolemia in patients with high-dose statin therapy after renal transplantation. 2006 , 6, 205-8	47
306	Beneficios de la terapia combinada en la hiperlipemia. 2006 , 6, 63G-71G	0
305	Management of dyslipidemias in patients with diabetes and chronic kidney disease. 2006 , 1, 1090-9	47
304	Type of preexisting lipid therapy predicts LDL-C response to ezetimibe. 2006 , 40, 818-23	3
303	Cholesterol absorption inhibitors as a therapeutic option for hypercholesterolaemia. 2006 , 15, 1337-51	21
302	Is combined treatment with fenofibrate and ezetimibe safe and efficacious in patients with mixed hyperlipidemia?. 2006 , 3, 594-5	2
301	Non-low-density lipoprotein cholesterol-associated actions of ezetimibe: an overview. 2006 , 10, 851-66	24
300	Dual cholesterol inhibition with ezetimibe/simvastatin in pre-treated hypercholesterolaemic patients with coronary heart disease or diabetes mellitus: prospective observational cohort studies in clinical practice. 2007 , 23, 713-9	23
299	Efficacy and safety of ezetimibe/simvastatin versus simvastatin monotherapy in hypercholesterolemic patients with metabolic syndrome. 2007 , 5, 13-21	7
298	Cholesterol-lowering effect of ezetimibe in uridine diphosphate glucuronosyltransferase 1A-deficient (Gunn) rats. 2007 , 35, 1455-8	11
297	Endothelial function, arterial stiffness and lipid lowering drugs. 2007 , 11, 1143-60	27
296	[In-vitro study of the drug interactions between Miglitol, an alpha-glucosidase inhibitor, and adsorbents]. 2007 , 127, 2051-5	5
295	Pharmacogenetics and pharmacogenomics of cholesterol-lowering therapy. 2007 , 18, 164-73	37
294	[New insights and perspectives in the management of dyslipidemia]. 2007 , 28, 537-44	
293	Transporter-mediated uptake into cellular compartments. 2007 , 37, 1171-95	34
292	Treatment of hypercholesterolemia with ezetimibe in cardiac transplant recipients. 2007 , 26, 281-4	13
291	Primary biliary cirrhosis, hyperlipidemia, and atherosclerotic risk: a systematic review. 2007 , 194, 293-9	102

290	Ezetimibe: an update on the mechanism of action, pharmacokinetics and recent clinical trials. 2007 , 3, 441-50		48
289	Ezetimibe is effective when added to maximally tolerated lipid lowering therapy in patients with HIV. 2007 , 6, 15		39
288	2007 ESH-ESC Guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). 2007 , 16, 135-232		247
287	Commentary: bioavailability of flavonoids and polyphenols: call to arms. 2007 , 4, 803-6		106
286	[ESH/ESC 2007 Guidelines for the management of arterial hypertension]. 2007 , 60, 968.e1-94		29
285	Pharmacokinetics of the oral direct renin inhibitor aliskiren alone and in combination with irbesartan in renal impairment. <i>Clinical Pharmacokinetics</i> , 2007 , 46, 661-75	6.2	54
284	Treatment with ezetimibe plus low-dose atorvastatin compared with higher-dose atorvastatin alone: is sufficient cholesterol-lowering enough to inhibit platelets?. 2007 , 49, 1035-42		76
283	Zetia: inhibition of Niemann-Pick C1 Like 1 (NPC1L1) to reduce intestinal cholesterol absorption and treat hyperlipidemia. 2007 , 14, 99-108		124
282	Lipid-Lowering Therapy. 2007 , 1087-1099		1
281	Biliary secretion and excretion in health and disease: Current concepts. 2007 , 6, 15-27		103
280	Disposition of the cholesterol absorption inhibitor ezetimibe in mdr1a/b (-/-) mice. 2007 , 96, 3478-84		7
279	The pharmacologic elegance of inhibiting cholesterol absorption and synthesis while providing a homeostatic balance. 2007 , 21 Suppl 2, 21-6		6
278	Ezetimibe-associated adverse effects: what the clinician needs to know. 2008 , 62, 88-96		37
277	Intestinal UGTs as potential modifiers of pharmacokinetics and biological responses to drugs and xenobiotics. 2007 , 3, 93-107		76
276	Drug-induced liver injury associated with ezetimibe therapy. 2007 , 52, 602-5		14
275	Isocoumarin-based inhibitors of pancreatic cholesterol esterase. 2008 , 16, 5285-94		50
274	Long-term efficacy and safety of ezetimibe 10 mg in patients with homozygous sitosterolemia: a 2-year, open-label extension study. 2008 , 62, 1499-510		41
273	Optimal time to take once-daily oral medications in clinical practice. 2008 , 62, 1560-71		8

272	Ezetimibe effectively lowers LDL-cholesterol in cardiac allograft recipients on stable statin therapy. 2008 , 22, 639-44	4
271	Simvastatin-ezetimibe-induced hepatic failure necessitating liver transplantation. 2008 , 28, 1188-93	24
270	Effectiveness of ezetimibe alone or in combination with twice a week Atorvastatin (10 mg) for statin intolerant high-risk patients. 2008 , 101, 483-5	57
269	Self-nanoemulsifying granules of ezetimibe: design, optimization and evaluation. 2008 , 35, 183-92	116
268	Adverse drug reactions in patients with cardiovascular disease. 2008 , 33, 703-68	24
267	Stability-Indicating HPTLC Method for Simultaneous Determination of Ezetimibe and Simvastatin. 2008 , 67, 101-107	33
266	Effectiveness of ezetimibe in routine clinical practice. Effect on lipid profile and other laboratory parameters. 2008 , 55, 165-9	0
265	Ezetimibe-related myopathy: A systematic review. 2008 , 2, 328-34	28
264	Changes in cholesterol kinetics following sugar cane policosanol supplementation: a randomized control trial. 2008 , 7, 17	11
263	Formulation and in vivo evaluation of self-nanoemulsifying granules for oral delivery of a combination of ezetimibe and simvastatin. 2008 , 34, 1285-96	44
262	Safety and efficacy of ezetimibe with low doses of simvastatin in heart transplant recipients. 2008 , 27, 685-8	13
261	Lipid profiles of patients with a transplanted heart before and after the operation. 2008 , 40, 263-6	3
260	Ezetimibe in the treatment of uncontrolled hyperlipidemia in kidney transplant patients. 2008 , 40, 3492-5	13
259	Dyslipidaemia and cardiorenal disease: mechanisms, therapeutic opportunities and clinical trials. 2008 , 196, 823-34	47
258	Drug-drug interaction with statins. 2008 , 1, 105-13	21
257	Predictors of uncontrolled hyperlipidaemia in high-risk ambulatory patients in primary care. 2008 , 24, 1659-68	5
256	The effects of low-dose simvastatin and ezetimibe compared to high-dose simvastatin alone on post-fat load endothelial function in patients with metabolic syndrome: a randomized double-blind crossover trial. 2008 , 52, 145-50	37
255	Disposition of ezetimibe is influenced by polymorphisms of the hepatic uptake carrier OATP1B1. 2008 , 18, 559-68	75

254	Combination therapy in cholesterol reduction: focus on ezetimibe and statins. 2008 , 4, 267-78		17
253	Pharmacotherapy of Mixed Hyperlipidemia with Ezetimibe-Fenofibrate Combination Therapy. 2009 , 1, CMT.S2036		1
252	Colesevelam hydrochloride: usefulness of a specifically engineered bile acid sequestrant for lowering LDL-cholesterol. 2009 , 16, 1-9		22
251	Changes in cholesterol absorption and cholesterol synthesis caused by ezetimibe and/or simvastatin in men. 2009 , 50, 2117-23		47
250	Safety and effectiveness of ezetimibe in liver transplant recipients with hypercholesterolemia. 2009 , 15, 504-8		46
249	Lack of pharmacokinetic interaction of mipomersen sodium (ISIS 301012), a 2'RO-methoxyethyl modified antisense oligonucleotide targeting apolipoprotein B-100 messenger RNA, with simvastatin and ezetimibe. <i>Clinical Pharmacokinetics</i> , 2009 , 48, 39-50	6.2	83
248	Comparison of the efficacy of administering a combination of ezetimibe plus fenofibrate versus atorvastatin monotherapy in the treatment of dyslipidemia. 2009 , 8, 56		5
247	Safety of the combination of intensive cholesterol-lowering therapy with oral anticoagulation medication in elderly patients with atrial fibrillation: a randomized, double-blind, placebo-controlled study. 2009 , 26, 585-93		9
246	Ezetimibe/simvastatin. 2009 , 8, 715-25		7
245	Traitements des dyslipidémies: moyens pharmacologiques. Indications et recommandations thérapeutiques. 2010 , 7, 1-11		
244	Atherosclerosis I: LDL Cholesterol Lowering. 2010 , 303-330		
243	Ezetimibe therapy and its influence on oxidative stress and fibrinolytic activity. 2010 , 103, 428-33		19
242	System-dependent outcomes during the evaluation of drug candidates as inhibitors of cytochrome P450 (CYP) and uridine diphosphate glucuronosyltransferase (UGT) enzymes: human hepatocytes versus liver microsomes versus recombinant enzymes. 2010 , 25, 16-27		61
241	Pleiotropic effects of ezetimibe: do they really exist?. 2010 , 633, 62-70		39
240	Ezetimibe as a potential treatment for non-alcoholic fatty liver disease: is the intestine a modulator of hepatic insulin sensitivity and hepatic fat accumulation?. 2010 , 15, 590-5		10
239	Ezetimibe reverses the inhibitory effects of dietary cholesterol on mammary tumorigenesis in rats. 2010 , 127, 791-5		2
238	Synergistic influence of Abcb1 and Abcc2 on disposition and sterol lowering effects of ezetimibe in rats. 2010 , 99, 422-9		10
237	Study of surfactant combinations and development of a novel nanoemulsion for minimising variations in bioavailability of ezetimibe. 2010 , 76, 410-20		142

236	Lack of clinically relevant drug-drug interactions when dalcetrapib is co-administered with ezetimibe. 2010 , 70, 825-33	11
235	Transporters as drug targets: discovery and development of NPC1L1 inhibitors. 2010 , 87, 117-21	16
234	Pharmacokinetic and pharmacodynamic interactions between the immunosuppressant sirolimus and the lipid-lowering drug ezetimibe in healthy volunteers. 2010 , 87, 663-7	20
233	Potential therapeutic uses for ezetimibe beyond lowering LDL-c to decrease cardiovascular events. 2010 , 12, 958-66	15
232	The role of colestevam hydrochloride in hypercholesterolemia and type 2 diabetes mellitus. 2010 , 44, 1196-206	13
231	Update on the efficacy and safety of combination ezetimibe plus statin therapy. 2010 , 5, 655-684	28
230	Novel nanoemulsion for minimizing variations in bioavailability of ezetimibe. 2010 , 18, 506-19	32
229	Effect of the bile acid sequestrant colestevam on the pharmacokinetics of pioglitazone, repaglinide, estrogen estradiol, norethindrone, levothyroxine, and glyburide. 2010 , 50, 554-65	16
228	Epidemiological link between low cholesterol and suicidality: a puzzle never finished. 2011 , 14, 268-87	20
227	Persisting thrombin activity in elderly patients with atrial fibrillation on oral anticoagulation is decreased by anti-inflammatory therapy with intensive cholesterol-lowering treatment. 2011 , 5, 273-80	15
226	Ezetimibe--a new approach in hypercholesterolemia management. 2011 , 63, 1335-48	30
225	Influence of age, gender, and race on the efficacy of adding ezetimibe to atorvastatin vs. atorvastatin up-titration in patients at moderately high or high risk for coronary heart disease. 2011 , 153, 141-7	9
224	Effects of ezetimibe on atherosclerosis in preclinical models. 2011 , 215, 266-78	30
223	The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. 2011 , 377, 2181-92	1627
222	Efficacy of ezetimibe as monotherapy or combination therapy in hypercholesterolemic patients with and without diabetes. 2011 , 58, 86-94	15
221	Clinical usefulness of additional treatment with ezetimibe in patients with coronary artery disease on statin therapy. - From the viewpoint of cholesterol metabolism.-. 2011 , 75, 2496-504	15
220	Design and characterization of nanocrystal formulations containing ezetimibe. 2011 , 59, 41-5	30
219	A sharp study, but with blunted conclusions. 2011 , 24, 684-5	1

218	The ezetimibe Jonah: the trials and tribulations of an unlucky drug. 2011 , 65, 1207-8	18
217	Drug interactions between the immunosuppressant tacrolimus and the cholesterol absorption inhibitor ezetimibe in healthy volunteers. 2011 , 89, 524-8	11
216	Treatment of atherogenic liver based on the pathogenesis of nonalcoholic fatty liver disease: a novel approach to reduce cardiovascular risk?. 2011 , 42, 337-53	29
215	Effects of UDP-glucuronosyltransferase polymorphisms on the pharmacokinetics of ezetimibe in healthy subjects. 2011 , 67, 39-45	16
214	Assessment of potential pharmacokinetic interactions of ezetimibe/simvastatin and extended-release niacin tablets in healthy subjects. 2011 , 67, 483-92	9
213	Preparation, Characterization, and In Vitro Evaluation of Ezetimibe Binary Solid Dispersions with Poloxamer 407 and PVP K30. 2011 , 6, 107-114	12
212	First-pass metabolism via UDP-glucuronosyltransferase: a barrier to oral bioavailability of phenolics. 2011 , 100, 3655-81	205
211	Nanocarrier for the enhanced bioavailability of a cardiovascular agent: in vitro, pharmacodynamic, pharmacokinetic and stability assessment. 2011 , 403, 46-56	76
210	Safety review of combination drugs for hyperlipidemia. 2011 , 10, 363-71	14
209	Intestinal sterol transporters and cholesterol absorption inhibition. 2011 , 22, 467-78	20
208	Lipid-lowering effects of ezetimibe and simvastatin in combination. 2011 , 9, 131-45	13
207	High-density lipoprotein (HDL) cholesterol: leveraging practice-based biobank cohorts to characterize clinical and genetic predictors of treatment outcome. 2011 , 11, 162-73	8
206	Combinations of ezetimibe with nonstatin drug regimens affecting lipid metabolism. 2011 , 9, 355-66	16
205	Dietary intake of plant sterols stably increases plant sterol levels in the murine brain. 2012 , 53, 726-35	71
204	Statins and their interactions with other lipid-modifying medications: safety issues in the elderly. 2012 , 3, 35-46	12
203	Molecular mechanism of altered ezetimibe disposition in nonalcoholic steatohepatitis. 2012 , 40, 450-60	47
202	Ezetimibe: its novel effects on the prevention and the treatment of cholesterol gallstones and nonalcoholic Fatty liver disease. 2012 , 2012, 302847	27
201	Quantitative prediction of intestinal glucuronidation of drugs in rats using in vitro metabolic clearance data. 2012 , 27, 171-80	17

200	Impact of efavirenz on intestinal metabolism and transport: insights from an interaction study with ezetimibe in healthy volunteers. 2012 , 91, 506-13	30
199	Glycosphingolipid synthesis inhibitor AMP-DNM lowers plasma cholesterol levels by promoting fecal cholesterol excretion without inhibiting cholesterol absorption. 2012 , 7, 241-248	
198	A novel local recycling mechanism that enhances enteric bioavailability of flavonoids and prolongs their residence time in the gut. 2012 , 9, 3246-58	28
197	Method for predicting human intestinal first-pass metabolism of UGT substrate compounds. 2012 , 42, 980-8	8
196	Use of a multistaged time-dependent inhibition assay to assess the impact of intestinal metabolism on drug-drug interaction potential. 2012 , 40, 467-73	4
195	Pharmacokinetics and safety of ezetimibe/simvastatin combination tablet: an open-label, single-dose study in healthy Chinese subjects. 2012 , 32, 791-8	8
194	Pharmacokinetics of aliskiren in patients with end-stage renal disease undergoing haemodialysis. <i>Clinical Pharmacokinetics</i> , 2012 , 51, 661-9	6.2 4
193	Eficacia bioquímica y beneficio clínico de la doble inhibición con ezetimiba y simvastatina. 2012 , 12, 2-7	
192	Pleiotropic effects of ezetimibe/simvastatin vs. high dose simvastatin. 2012 , 158, 400-4	31
191	Role and Clinical Consequences of Human UDP-Glucuronosyltransferases. 2012 , 1	
190	ANALYTICAL LC-MS/MS METHOD FOR EZETIMIBE AND ITS APPLICATION FOR PHARMACOKINETIC STUDY. 2012 , 35, 141-152	4
189	Differences in synthesis and absorption of cholesterol of two effective lipid-lowering therapies. 2012 , 45, 1095-101	10
188	Long-term outcome after liver transplantation. 2012 , 79, 169-89	19
187	Identification of drugs and drug metabolites as substrates of multidrug resistance protein 2 (MRP2) using triple-transfected MDCK-OATP1B1-UGT1A1-MRP2 cells. 2012 , 165, 1836-1847	51
186	Atorvastatin 10 mg plus ezetimibe 10mg compared with atorvastatin 20 mg: impact on the lipid profile in Japanese patients with abnormal glucose tolerance and coronary artery disease. 2012 , 59, 50-6	34
185	A review of the rationale for additional therapeutic interventions to attain lower LDL-C when statin therapy is not enough. 2012 , 14, 33-40	13
184	A Rapid and Sensitive LC-MS Method for Determination of Ezetimibe Concentration in Human Plasma: Application to a Bioequivalence Study. 2013 , 76, 1667-1675	15
183	Gender-dependent differences in uridine 5Rdiphospho-glucuronosyltransferase have implications in metabolism and clearance of xenobiotics. 2013 , 9, 1555-69	9

182	Clinical significance of organic anion transporting polypeptides (OATPs) in drug disposition: their roles in hepatic clearance and intestinal absorption. 2013 , 34, 45-78	285
181	The effects of flavonoids on the ABC transporters: consequences for the pharmacokinetics of substrate drugs. 2013 , 9, 267-85	32
180	Incremental lowering of low-density lipoprotein cholesterol with ezetimibe 20 mg vs 10 mg daily in patients receiving concomitant statin therapy. 2013 , 29, 1395-9	3
179	PANACEA or much a do about nothing: effect of a statin and ezetimibe on postprandial lipaemia and endothelial function in the metabolic syndrome. 2013 , 227, 32-4	
178	New formulation approaches to improve solubility and drug release from fixed dose combinations: case examples pioglitazone/glimepiride and ezetimibe/simvastatin. 2013 , 84, 208-18	51
177	Substrate selectivity of human intestinal UDP-glucuronosyltransferases (UGTs): in silico and in vitro insights. 2013 , 45, 231-52	15
176	A reappraisal of the risks and benefits of treating to target with cholesterol lowering drugs. 2013 , 73, 1025-54	18
175	RP-HPLC-UV Determination of ezetimibe in serum: Method development, validation and application to patients chronically receiving the drug. 2013 , 25, 483-502	2
174	Intestinal and hepatic niemann-pick c1-like 1. 2013 , 37, 240-8	21
173	Ezetimibe. 2013 , 1-4	
172	Fungal biotransformation of ezetimibe. 2014 , 28, 934-940	
171	Pharmacokinetic non-interaction analysis in a fixed-dose formulation in combination of atorvastatin and ezetimibe. 2014 , 5, 261	8
170	The effects of mild or moderate hepatic impairment on the pharmacokinetics, safety, and tolerability of naloxegol. 2014 , 54, 1368-74	24
169	Hepatic microsomal UDP-glucuronosyltransferase (UGT) activities in the microminipig. 2014 , 35, 313-20	18
168	Species differences in intestinal glucuronidation activities between humans, rats, dogs and monkeys. 2014 , 44, 205-16	26
167	Cardiometabolic impact of non-statin lipid lowering therapies. 2014 , 16, 390	5
166	Understanding the transport properties of metabolites: case studies and considerations for drug development. 2014 , 42, 650-64	42
165	Regioselective glucuronidation of the isoflavone calycosin by human liver microsomes and recombinant human UDP-glucuronosyltransferases. 2014 , 220, 231-40	15

164	Development of optimized supersaturable self-nanoemulsifying systems of ezetimibe: effect of polymers and efflux transporters. 2014 , 11, 479-92	33
163	[Does ezetimibe combined with simvastatin increase the risk of renal failure]. 2014 , 46, 451-2	1
162	Formulation and in Vitro Evaluation of Self-microemulsifying Drug Delivery System Containing Fixed-Dose Combination of Atorvastatin and Ezetimibe. 2015 , 63, 423-30	7
161	Ezetimibe for primary hypercholesterolemia. 2015 ,	
160	Comparative study on solid self-nanoemulsifying drug delivery and solid dispersion system for enhanced solubility and bioavailability of ezetimibe. 2015 , 10, 6147-59	27
159	Efficacy and safety of ezetimibe monotherapy in children with heterozygous familial or nonfamilial hypercholesterolemia. 2015 , 166, 1377-84.e1-3	43
158	Efficacy of ezetimibe is not related to NPC1L1 gene polymorphisms in a pilot study of Chilean hypercholesterolemic subjects. 2015 , 19, 45-52	3
157	Quantitative Rationalization of Gemfibrozil Drug Interactions: Consideration of Transporters-Enzyme Interplay and the Role of Circulating Metabolite Gemfibrozil 1-O- β -Glucuronide. 2015 , 43, 1108-18	54
156	Aminolysis of ezetimibe. 2015 , 107, 495-500	2
155	Ezetimibe stimulates intestinal glucagon-like peptide 1 secretion via the MEK/ERK pathway rather than dipeptidyl peptidase 4 inhibition. 2015 , 64, 633-41	12
154	Impact of a cholesterol membrane transporter β inhibition on vitamin D absorption: A double-blind randomized placebo-controlled study. 2015 , 81, 338-342	4
153	Asociaci3n de simvastatina con ezetimiba como alternativa terap6utica en el control lip6dico de enfermos renales cr6nicos en estadio 3-4. Resultados a un a6o. 2015 , 36, 1-7	
152	[Author β reply]. 2015 , 47, 389-91	
151	Ezetimibe plus simvastatin for the treatment of hypercholesterolemia. 2015 , 16, 1255-62	11
150	Triple Recycling Processes Impact Systemic and Local Bioavailability of Orally Administered Flavonoids. 2015 , 17, 723-36	32
149	Preparation and pharmacodynamic assessment of ezetimibe nanocrystals: Effect of P-gp inhibitory stabilizer on particle size and oral absorption. 2015 , 135, 756-764	17
148	Enhancement of dissolution and bioavailability of ezetimibe by amorphous solid dispersion nanoparticles fabricated using supercritical antisolvent process. 2015 , 45, 641-649	25
147	Application of Static Models to Predict Midazolam Clinical Interactions in the Presence of Single or Multiple Hepatitis C Virus Drugs. 2016 , 44, 1372-80	5

146	Employing an optimized spray-drying process to produce ezetimibe tablets with an improved dissolution profile. 2016 , 46, 583-592	13
145	Appropriate risk criteria for OATP inhibition at the drug discovery stage based on the clinical relevancy between OATP inhibitors and drug-induced adverse effect. 2016 , 31, 333-339	7
144	Rapid and selective determination of pitavastatin calcium in presence of its degradation products and co-formulated drug by first-derivative micelle-enhanced and synchronous fluorimetric methods. 2016 , 6, 107246-107255	1
143	Reduction of ischemic events in Improved Reduction of Outcomes: Vytorin Efficacy International Trial: Intensive cholesterol lowering or ezetimibe antithrombotic effects?. 2016 , 172, 42-4	1
142	Role of enterohepatic recirculation in drug disposition: cooperation and complications. 2016 , 48, 281-327	32
141	Approaches to intravenous clinical pharmacokinetics: Recent developments with isotopic microtracers. 2016 , 56, 11-23	20
140	Effect of anti-hyperlipidemia drugs on the alpha-tocopherol concentration and their potential for murine malaria infection. 2016 , 115, 69-75	6
139	The safety of ezetimibe and simvastatin combination for the treatment of hypercholesterolemia. 2016 , 15, 559-69	13
138	Design, optimization, and evaluation of ezetimibe solid supersaturatable self-nanoemulsifying drug delivery for enhanced solubility and dissolution. 2016 , 46, 153-168	7
137	Ezetimibe enhances and stabilizes anticoagulant effect of warfarin. 2017 , 32, 47-54	9
136	Transport-Glucuronidation Classification System and PBPK Modeling: New Approach To Predict the Impact of Transporters on Disposition of Glucuronides. 2017 , 14, 2884-2898	7
135	Glucuronidation: driving factors and their impact on glucuronide disposition. 2017 , 49, 105-138	41
134	Hepatitis C virus may have an entero-hepatic cycle which could be blocked with ezetimibe. 2017 , 102, 51-55	1
133	Effect of ezetimibe on plasma adipokines: a systematic review and meta-analysis. 2017 , 83, 1380-1396	11
132	Progress in Prediction and Interpretation of Clinically Relevant Metabolic Drug-Drug Interactions: a Minireview Illustrating Recent Developments and Current Opportunities. 2017 , 3, 36-49	24
131	Ezetimibe for the prevention of cardiovascular disease and all-cause mortality events. 2017 ,	2
130	Selectivity in the Efflux of Glucuronides by Human Transporters: MRP4 Is Highly Active toward 4-Methylumbelliferone and 1-Naphthol Glucuronides, while MRP3 Exhibits Stereoselective Propranolol Glucuronide Transport. 2017 , 14, 3299-3311	7
129	Pharmacokinetic drug evaluation of ezetimibe + simvastatin for the treatment of hypercholesterolemia. 2017 , 13, 1099-1104	13

128	A New Pathway for Protein Haptenation by β -Lactams. 2017 , 23, 13986-13994	7
127	Comparison of Pharmacokinetics and Safety of a Fixed-dose Combination of Rosuvastatin and Ezetimibe Versus Separate Tablets in Healthy Subjects. 2017 , 39, 1799-1810	9
126	Clinical Drug-Drug Interactions Through Cytochrome P450 3A (CYP3A) for the Selective ALK Inhibitor Alectinib. 2017 , 6, 280-291	28
125	Ezetimibe inhibits platelet activation and uPAR expression on endothelial cells. 2017 , 227, 858-862	11
124	The effects of dietary and herbal phytochemicals on drug transporters. 2017 , 116, 45-62	33
123	Pharmacokinetic and pharmacodynamic interaction between ezetimibe and rosuvastatin in healthy male subjects. 2017 , 11, 3461-3469	10
122	Pharmacokinetic drug interaction between atorvastatin and ezetimibe in healthy Korean volunteers. 2017 , 25, 202-208	4
121	Pharmacokinetics, pharmacodynamics and clinical efficacy of non-statin treatments for hypercholesterolemia. 2018 , 14, 9-15	10
120	A rapid and sensitive supercritical fluid chromatography/tandem mass spectrometry method for detection of ezetimibe in dog plasma and its application in pharmacokinetic studies. 2018 , 1073, 177-182	5
119	Ezetimibe for the prevention of cardiovascular disease and all-cause mortality events. 2018 , 11, CD012502	27
118	Pharmacokinetics of fixed-dose combination of rosuvastatin 20 mg and ezetimibe 10 mg compared to concurrent administration of individual tablets in healthy Korean subjects. 2018 , 26, 16-24	5
117	Adding ezetimibe to statin therapy: latest evidence and clinical implications. 2018 , 7, 212534	28
116	Simultaneous quantitation of rosuvastatin and ezetimibe in human plasma by LC-MS/MS: Pharmacokinetic study of fixed-dose formulation and separate tablets. 2018 , 32, e4291	2
115	Clinical Lipidology and the Prevention of Vascular Disease: Time for Personalized Therapy. 2018 , 104, 269-281	1
114	Short-Term Efficacy and Safety of Adding Ezetimibe to Current Regimen of Lipid-Lowering Drugs in Human Immunodeficiency Virus-Infected Thai Patients Treated with Protease Inhibitors. 2018 , 71, 220-224	2
113	Long term substrate reduction therapy with ezetimibe alone or associated with statins in three adult patients with lysosomal acid lipase deficiency. 2018 , 13, 24	10
112	Combined spectroscopic and quantum chemical approach to study the effect of hydrogen bonding interactions in ezetimibe. 2019 , 206, 246-253	7
111	Enterohepatic circulation of glucuronide metabolites of drugs in dog. 2019 , 7, e00502	6

110	OATP1B3-1B7 (LST-3TM12) Is a Drug Transporter That Affects Endoplasmic Reticulum Access and the Metabolism of Ezetimibe. 2019 , 96, 128-137	5
109	Biocatalysis as Useful Tool in Asymmetric Synthesis: An Assessment of Recently Granted Patents (2014-2019). 2019 , 9, 802	47
108	Drug Treatment of Hyperlipidemia in Chinese Patients: Focus on the Use of Simvastatin and Ezetimibe Alone and in Combination. 2019 , 19, 237-247	6
107	Development, in-vitro and in-vivo evaluation of ezetimibe-loaded solid lipid nanoparticles and their comparison with marketed product. 2019 , 51, 583-590	37
106	Evaluating the efficacy and safety of atorvastatin + ezetimibe in a fixed-dose combination for the treatment of hypercholesterolemia. 2019 , 20, 917-928	6
105	Increased Paracetamol Bioavailability after Sleeve Gastrectomy: A Crossover Pre- vs. Post-Operative Clinical Trial. 2019 , 8,	7
104	Central composite designed ezetimibe solid dispersion for dissolution enhancement: synthesis and evaluation. 2019 , 10, 643-658	7
103	Development of a joint population pharmacokinetic model of ezetimibe and its conjugated metabolite. 2019 , 128, 18-26	4
102	On the population pharmacokinetics and the enterohepatic recirculation of total ezetimibe. 2019 , 49, 446-456	3
101	Inhibition of Niemann-Pick C1-like protein 1 by ezetimibe reduces uptake of deuterium-labeled vitamin D in mice. 2020 , 197, 105504	9
100	Efficacy and safety of add on therapies in patients with hypercholesterolemia undergoing statin therapy. 2020 , 21, 2137-2151	3
99	Efficacy and Tolerability of a Fixed-Dose Combination of Rosuvastatin and Ezetimibe Compared with a Fixed-Dose Combination of Simvastatin and Ezetimibe in Brazilian Patients with Primary Hypercholesterolemia or Mixed Dyslipidemia: A Multicenter, Randomized Trial. 2020 , 93, 100595	4
98	Biotransformation: Impact and Application of Metabolism in Drug Discovery. 2020 , 11, 2087-2107	16
97	Cholesterol Review: A Metabolically Important Molecule. 2020 , 26, 1514-1523	18
96	Human variability in isoform-specific UDP-glucuronosyltransferases: markers of acute and chronic exposure, polymorphisms and uncertainty factors. 2020 , 94, 2637-2661	11
95	Development of TsDPEN based imine-containing ligands for the copper-catalysed asymmetric Kinugasa reaction.. 2020 , 10, 18107-18114	3
94	Early cell-autonomous accumulation of neutral lipids during infection promotes mycobacterial growth. 2020 , 15, e0232251	2
93	Post-Transplant Cholesterol and Triglyceride Behavior: Effects of Sex, Age of the Recipient, and Type of Donor. 2020 , 52, 1157-1162	3

92	A Review of the Efficacy and Tolerability of Bempedoic Acid in the Treatment of Hypercholesterolemia. 2020 , 20, 535-548	13
91	Pharmacokinetics of current and emerging treatments for hypercholesterolemia. 2020 , 16, 371-385	6
90	Rosuvastatin/Ezetimibe: A Review in Hypercholesterolemia. 2020 , 20, 381-392	10
89	An overview of rosuvastatin/ezetimibe association for the treatment of hypercholesterolemia and mixed dyslipidemia. 2020 , 21, 531-539	8
88	Ezetimibe Prevents Ischemia/Reperfusion-Induced Oxidative Stress and Up-Regulates Nrf2/ARE and UPR Signaling Pathways. 2020 , 9,	3
87	Effects of statins and exercise on postprandial lipoproteins in metabolic syndrome vs metabolically healthy individuals. 2021 , 87, 955-964	2
86	Drugs for the Skinternist. 2021 , 430-444.e3	
85	SnapshotDx Quiz: February 2021. 2021 , 141, e15-e19	
84	Enzyme Kinetics of Uridine Diphosphate Glucuronosyltransferases (UGTs). 2021 , 2342, 301-338	1
83	Ezetimibe. 2021 , 91-101	
82	High-pressure asymmetric hydrogenation in a customized flow reactor and its application in multi-step flow synthesis of chiral drugs. 1	1
81	Pharmacokinetic Interaction Among Ezetimibe, Rosuvastatin, and Telmisartan. 2021 , 10, 1290-1296	1
80	Atherosclerosis: Cholesterol Management. 1-36	
79	One-step modification to identify dual-inhibitors targeting both pancreatic triglyceride lipase and Niemann-Pick C1-like 1. 2021 , 216, 113358	5
78	Three Musketeers for Lowering Cholesterol: Statins, Ezetimibe and Evolocumab. 2021 , 28, 1025-1041	3
77	Lipid Optimization in Lower Extremity Peripheral Arterial Disease. 2021 , 76, 542-554	1
76	Trends in the Utilization of Lipid-Lowering Medications in Australia: An Analysis of National Pharmacy Claims Data. 2021 , 100880	2
75	Aryl Radical Activation of C-O Bonds: Copper-Catalyzed Deoxygenative Difluoromethylation of Alcohols. 2021 , 143, 9952-9960	7

74	Applications of fluorine to the construction of bioisosteric elements for the purposes of novel drug discovery. 2021 , 16, 1261-1286	8
73	Improving Catalytic Activity and Reversing Enantio-Specificity of α -Transaminase by Semi-Rational Engineering en Route to Chiral Bulky α -Amino Esters. 2021 , 13, 3396-3400	0
72	Synthesis of deuterium labeled ezetimibe and its glucuronide conjugate. 2021 , 329, 695-700	
71	Impact of gastrointestinal tract variability on oral drug absorption and pharmacokinetics: An UNGAP review. 2021 , 162, 105812	41
70	Hepatoenteric recycling is a new disposition mechanism for orally administered phenolic drugs and phytochemicals in rats. 2021 , 10,	1
69	COMPATIBILITY STUDY BETWEEN PRAVASTATIN AND EZETIMIBE, AND PHARMACEUTICAL EXCIPIENTS USED IN FIXED-DOSE COMBINATION TABLET. 84-89	
68	Approved drugs ezetimibe and disulfiram enhance mitochondrial Ca uptake and suppress cardiac arrhythmogenesis. 2021 , 178, 4518-4532	3
67	A systems-level study reveals host-targeted repurposable drugs against SARS-CoV-2 infection. 2021 , 17, e10239	5
66	Deficiency of intestinal Bmal1 prevents obesity induced by high-fat feeding. 2021 , 12, 5323	8
65	A comparison of the effects of monotherapy with rosuvastatin, atorvastatin or ezetimibe versus combination treatment with rosuvastatin-ezetimibe and atorvastatin-ezetimibe on the integrity of vascular endothelial cells damaged by oxidized cholesterol. 2021 , 16, e0256996	0
64	Dyslipidemia: Current Therapies and Strategies to Overcome Barriers for Use. 2021 ,	0
63	Resolving the Egg and Cholesterol Intake Controversy: New Clinical Insights Into Cholesterol Regulation by the Liver and Intestine. 2021 ,	2
62	Polyphenols from Citrus Tacle Extract Endowed with HMGCR Inhibitory Activity: An Antihypercholesterolemia Natural Remedy. 2021 , 26,	0
61	How Does the Addition of KollidonVA64 Inhibit the Recrystallization and Improve Ezetimibe Dissolution from Amorphous Solid Dispersions?. <i>Pharmaceutics</i> , 2021 , 13,	6.4 4
60	Safety Considerations of Pharmacological Treatment. 2021 , 203-219	0
59	DYSLIPIDEMIAS. 2009 , 303-320	1
58	Non-systemic Intestine-Targeted Drugs. 2016 , 55, 1-44	6
57	LDL-cholesterol: The lower the better. 2019 , 31 Suppl 2, 16-27	6

56	Hepatic Niemann-Pick C1-like 1 regulates biliary cholesterol concentration and is a target of ezetimibe. 2007 , 117, 1968-78	279
55	The Combination of Ezetimibe and Statin: A New Treatment for Hypercholesterolemia. 2007 , 3, 182618680700300	
54	Characterization and Bioavailability of Wogonin by Different Administration Routes in Beagles. 2016 , 22, 3737-3745	6
53	Pharmacological Strategies beyond Statins: Ezetimibe and PCSK9 Inhibitors. 2019 , 8, 183-191	8
52	Modulation of Hepatic MRP3/ABCC3 by Xenobiotics and Pathophysiological Conditions: Role in Drug Pharmacokinetics. 2019 , 26, 1185-1223	9
51	New options in the treatment of lipid disorders in HIV-infected patients. 2009 , 3, 31-7	12
50	Ezetimibe as potential treatment for cholesterol gallstones: the need for clinical trials. 2010 , 16, 1555-7	10
49	The efficacy and safety of ezetimibe and low-dose simvastatin as a primary treatment for dyslipidemia in renal transplant recipients. 2009 , 24, 233-7	8
48	The combination of Ezetimibe and Statin: a new treatment for hypercholesterolemia. 2007 , 3, 12	3
47	Stability Indicating RP-HPLC Method for Simultaneous Determination of Simvastatin and Ezetimibe from Tablet Dosage Form. 2010 , 72, 204-10	20
46	Lipid lowering in patients 75 years and older. 2021 , 13, 526-532	0
45	Safety of Dyslipidemic Agents. 2006 , 389-408	
44	Atherosclerosis and lipoprotein metabolism. 2007 , 321-330	1
43	The Importance of Gut Wall Metabolism in Determining Drug Bioavailability. 2008 , 333-357	2
42	Clinical Pharmacology of Cardiovascular Drugs. 2009 , 367-402	
41	Ezetimibe and Cholesterol Absorption.	
40	Atherosclerosis and lipoprotein metabolism. 2012 , 285-293	
39	Formulation and Evaluation of Self-Nanoemulsifying Powder of Ezetimibe. 2014 , 1, 1-8	

38 Cardiovascular Disease. **2019**, 101-151

37 Ezetimibe: A Review of Analytical Methods for the Drug Substance, Pharmaceutical Formulations and Biological Matrices. **2020**, 1-16

0

36 Stability indicating liquid chromatographic method for the simultaneous determination of rosuvastatin and ezetimibe in pharmaceutical formulations. **2014**, 4, 405-11

4

35 Emerging Non-statin Treatment Options for Lowering Low-Density Lipoprotein Cholesterol. **2021**, 8, 789931

2

34 Biochemical risk factors of atherosclerotic cardiovascular disease: from a narrow and controversial approach to an integral approach and precision medicine.. **2021**,

33 Drug-Drug Interactions in People Living with HIV at Risk of Hepatic and Renal Impairment: Current Status and Future Perspectives.. **2022**,

0

32 The safety and efficacy of Ezetimibe Plus Statins on ASVD and Related Diseases. **2021**, 12, 1857-1871

0

31 Niemann-Pick C1-Like 1 inhibitors for reducing cholesterol absorption.. **2022**, 230, 114111

3

30 On the population pharmacokinetics and the enterohepatic recirculation of hyzetimibe and its main metabolite in Chinese healthy subjects.. **2021**,

29 Lipid-Targeted Atherosclerotic Risk Reduction in Older Adults: A Review.. **2022**, 7,

28 Antilipidemic ezetimibe induces regression of endometriotic explants in a rat model of endometriosis with its anti-inflammatory and anti-angiogenic effects.. **2022**, 1

27 Drug Interactions: What Are Important Drug Interactions for the Most Commonly Used Medications in Preventive Cardiology?. **2022**, 106, 389-399

1

26 Investigation of the Discriminatory Ability of Analytes for the Bioequivalence Assessment of Ezetimibe: Parent Drug, Metabolite, Total Form, and Combination of Parent Drug and Total Form.. **2022**, 106192

25 Targeted Strategy in Lipid-Lowering Therapy. *Biomedicines*, **2022**, 10, 1090

4.8 2

24 Phenols in Pharmaceuticals: Analysis of a Recurring Motif.. *Journal of Medicinal Chemistry*, **2022**,

8.3 7

23 The Role of VEGF Family in Lipid Metabolism.. *Current Pharmaceutical Biotechnology*, **2022**,

2.6 1

22 Drugs for the skinternist. **2013**, 408-423.e3

21 Safety of ezetimibe in lipid-lowering treatment: systematic review and meta-analysis of randomised controlled trials and cohort studies. **2022**, 1, e000134

2

20 Precision Medicine for Diabetes and Dyslipidemia. **2022**, 65-87

19 Lowering LDL cholesterol: from mechanisms to therapies.

18 Co-Amorphous Formation of Simvastatin-Ezetimibe: Enhanced Physical Stability, Bioavailability and Cholesterol-Lowering Effects in LDLr^{-/-} Mice. *Pharmaceutics*, **2022**, 14, 1258 6.4 o

17 Guidelines for the Prevention of Symptomatic Cardiovascular Disease, Based upon the Presence of Coronary Artery Calcified Plaque Provided by the Society for the Prevention of Symptomatic Heart Disease. *World Journal of Cardiovascular Diseases*, **2022**, 12, 320-341 o o

16 New Therapeutic Approaches in Treatment of Dyslipidaemia A Narrative Review. *Pharmaceutics*, **2022**, 15, 839 5.2 o

15 Cholesterol-lowering drugs: Focus on Ezetimibe: Cholesterol-lowering drugs: Focus on ezetimibe. **2022**, 1, 14-24

14 Lipid Lowering Therapy: An Era Beyond Statins. **2022**, 101342 2

13 Orlistat and ezetimibe could differently alleviate the high-fat diet-induced obesity phenotype by modulating the gut microbiota. 13, o

12 Adherence to Clinical Guidelines on STATIN Prescribing Among Diabetic Patients Aged 40-5 Years Old in a Primary Care Setting: A Cross-Sectional Study. Volume 16, 1855-1863

11 Management of dyslipidemia after allogeneic hematopoietic stem cell transplantation. **2022**, 21,

10 Regulation of cholesterol homeostasis in health and diseases: from mechanisms to targeted therapeutics. **2022**, 7, 4

9 An Efficient, Simultaneous Electrochemical Assay of Rosuvastatin and Ezetimibe from Human Urine and Serum Samples. **2022**, 5, 90 o

8 Inhibitory Effect of Isoliquiritigenin in Niemann-Pick C1-Like 1-Mediated Cholesterol Uptake. **2022**, 27, 7494 o


7 Synthesis of Quaternary Lactams via Copper-Catalyzed Enantioconvergent Radical C(sp³)-C(sp²) Cross-Coupling with Organoboronate Esters. 1

6 Synthesis of Quaternary Lactams via Copper-Catalyzed Enantioconvergent Radical C(sp³)-C(sp²) Cross-Coupling with Organoboronate Esters. o

5 Drug-drug interactions involving combinations of antipsychotic agents with antidiabetic, lipid-lowering, and weight loss drugs. o

4 Pharmacokinetic Interactions and Tolerability of Rosuvastatin and Ezetimibe: A Randomized, Phase 1, Crossover Study in Healthy Chinese Participants. o

3 Novel approach to adherence assessment based on parent drug and metabolite pharmacokinetics: pilot study with spironolactone. o

- 2 Pharmacokinetics and bioequivalence of Ezetimibe tablet versus Ezetrol[®] :an open-label, randomized, two-sequence crossover study in healthy Chinese subjects. **2023**, 24, 
- 1 The effect of lipid-lowering therapies on the pro-inflammatory and anti-inflammatory properties of vascular endothelial cells. **2023**, 18, e0280741 